Division of Transplant Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Transplantation. 2019 Jul;103(7):1306-1322. doi: 10.1097/TP.0000000000002656.
Traditional histopathological allograft biopsy evaluation provides, within hours, diagnoses, prognostic information, and mechanistic insights into disease processes. However, proponents of an array of alternative monitoring platforms, broadly classified as "invasive" or "noninvasive" depending on whether allograft tissue is needed, question the value proposition of tissue histopathology. The authors explore the pros and cons of current analytical methods relative to the value of traditional and illustrate advancements of next-generation histopathological evaluation of tissue biopsies. We describe the continuing value of traditional histopathological tissue assessment and "next-generation pathology (NGP)," broadly defined as staining/labeling techniques coupled with digital imaging and automated image analysis. Noninvasive imaging and fluid (blood and urine) analyses promote low-risk, global organ assessment, and "molecular" data output, respectively; invasive alternatives promote objective, "mechanistic" insights by creating gene lists with variably increased/decreased expression compared with steady state/baseline. Proponents of alternative approaches contrast their preferred methods with traditional histopathology and: (1) fail to cite the main value of traditional and NGP-retention of spatial and inferred temporal context available for innumerable objective analyses and (2) belie an unfamiliarity with the impact of advances in imaging and software-guided analytics on emerging histopathology practices. Illustrative NGP examples demonstrate the value of multidimensional data that preserve tissue-based spatial and temporal contexts. We outline a path forward for clinical NGP implementation where "software-assisted sign-out" will enable pathologists to conduct objective analyses that can be incorporated into their final reports and improve patient care.
传统的组织病理学同种异体移植活检评估可在数小时内提供诊断、预后信息和对疾病过程的机制见解。然而,一系列替代监测平台的支持者,根据是否需要同种异体组织,广泛地分为“侵入性”或“非侵入性”,对组织病理学的价值主张提出了质疑。作者探讨了当前分析方法相对于传统方法的优缺点,并举例说明了组织活检的下一代组织病理学评估的进展。我们描述了传统组织病理学评估的持续价值和“下一代病理学(NGP)”,广义上定义为与数字成像和自动图像分析相结合的染色/标记技术。非侵入性成像和液体(血液和尿液)分析分别促进了低风险、全球器官评估和“分子”数据输出;而侵入性替代方法则通过创建与稳态/基线相比表达增加/减少的基因列表,促进了客观的“机制”见解。替代方法的支持者将其首选方法与传统组织病理学进行对比:(1)未能引用传统和 NGP 的主要价值——保留了可供无数客观分析使用的空间和推断的时间上下文,以及(2)对成像和软件引导分析的进步对新兴组织病理学实践的影响表示不熟悉。有代表性的 NGP 示例说明了保留基于组织的空间和时间上下文的多维数据的价值。我们概述了临床 NGP 实施的前进道路,其中“软件辅助签发报告”将使病理学家能够进行可纳入其最终报告的客观分析,从而改善患者护理。